ClinicalTrials.gg
CompletedNCT03393208Updated Jul 15, 2019Results posted

Glucophage Immediate Release (GIR) China Bioequivalence Study

A Phase 1 interventional study of Test GIR and Reference GIR in Healthy, sponsored by Merck KGaA, Darmstadt, Germany. Completed at 1 site in China. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2019-07-15.

Sponsored by Merck KGaA, Darmstadt, Germany · Phase 1, Interventional, and Other

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
44
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 113 studies testing metformin in Diabetes Mellitus — 7 open to participants now, 7 under way, 1 of them phase 3. Metformin · Diabetes Mellitus.

Enrollment
83rd of 112
44 · median 108
Started
2018
with 3 others
Phase 1
15 of 113
2 open now
Registered
93rd of 113
by date
Lead sponsor
3 of 113
Merck KGaA, Darmstadt, Germany

Among the 113 studies testing metformin in Diabetes Mellitus, this one is the 83rd largest by enrollment of the 112 interventional ones that give a count, is one of 4 that started in 2018, is one of 15 in phase 1, and was the 93rd registered.

Diabetes Mellitus

8,293 studies on the registry are indexed under Diabetes Mellitus; 1,074 are open to participants now.

Browse Diabetes Mellitus studies →

Open to participants now

7 of the 113 studies testing metformin in Diabetes Mellitus are open now, in 6 countries. Recruiting first, the newest first:

2 more — sign in →

By country, each count listing its studies:

All 7 open studies →

About metformin

Metformin: first FDA approval 1995 (GLUCOPHAGE), first EMA approval 2003. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 650 Diabetes Mellitus studies recruiting now, 357 (55%) set no upper age limit and 197 (30%) stop at 75 or younger; 88 take children under 18; 183 take healthy volunteers.

This study: 18 Years to 55 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 113 studies testing metformin in Diabetes Mellitus, or all of them as a file.
02

Study summary

The study will assess the bioequivalence between single doses of glucophage immediate release (GIR) test tablets and GIR reference tablets under fed and fasted state in healthy subjects.

03

Conditions studied

  • Healthy

Browse trials for

Keywords

  • Diabetes Mellitus
  • Glucophage Immediate Release (GIR)
  • Bioequivalence Study
04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants had given written before any trial-related activities
  • Chinese male and female participants (at least 1/4 of each gender per trial group)
  • Aged between 18 and 55 years, inclusive
  • Weighed: 50 to 80 kilogram (kg); (BMI): 18 to 30 kg per meter square
  • Nonsmoker since at least 3 months
  • Good physical and mental health status, determined on the basis of the medical history and a physical examination
  • All values for biochemistry and hematology tests of blood and urine within the normal range or showied no deviation as judged by the Investigator
  • recording (12-lead ECG) without signs of clinically relevant pathology was judged by the Investigator
  • Vital signs (blood pressure, pulse, body temperature, and respiration) in sitting position within the normal range or showing no clinically relevant deviation was judged by the Investigator
  • All women of (WOCBP) who were not nursing, were not pregnant, and were using highly effective methods of
  • Negative screen for alcohol and drugs of abuse (cannabis, benzodiazepines, barbiturates, opiates, cocaine, and methyl amphetamine) were screened at and on admission
  • Negative screen for hepatitis A virus (HAV) antibodies, surface antigen (HBsAg), virus (HCV) antibodies, (HIV) antibodies, and Treponema pallidum (TP) antibodies

Exclusion criteria

Exclusion Criteria:

  • Participation in a clinical trial within 90 days prior to first drug administration
  • Blood donation (equal or more than 500 milliliter [mL]) or significant blood loss within 90 days prior to first drug administration
  • Any surgical or medical condition, including findings in the medical history or in the pretrial assessments, or any other significant disease, that in the opinion of the Investigator, constitutes a risk or a for the participation of the participant in the trial or that could interfere with the trial objectives, conducted or evaluated
  • History of surgery of the gastrointestinal tract which could influence the gastrointestinal absorption and/or motility according to the Investigator's opinion
  • History or presence of relevant liver diseases or hepatic dysfunction Allergy: ascertained or presumptive to the active drug substance and/or formulations' ingredients; history of anaphylaxis to drugs or allergic reactions in general, which the Investigator considered affectted the outcome of the trial
  • Receipt of any prescription or nonprescription medication within 2 weeks before the first IMP administration, including multivitamins and herbal products (example, St John's Wort, or traditional Chinese medicines), except paracetamol
  • Renal failure or renal dysfunction ( \< 80 mL/minute) as assessed by using the estimated measure with the Modification of Diet in Renal Disease () equation
  • Known lack of participant compliance or inability to communicate or cooperate with the Investigator (example, language problem and poor mental status)
  • Nonacceptance of trial high-fat breakfast (example, vegetarians, vegans, and participants followed special diets)
  • Consumption of large quantities of methyl xanthine-containing beverages (> 5 cups of coffee/day or equivalent)
  • Consumption of grapefruit, cranberry or juices of these fruits, from 14 days prior to drug administration until collection of the last pharmacokinetic sample in Period 2
  • Any contraindication to Glucophage
  • Abnormal and chest X-ray finding at screening
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
44 participants (actual)

Study arms

  • Experimental
    First Test GIR (Fasting), Then Reference GIR (Fasting)

    Participants received a single oral dose of 500 milligram (mg) of test Glucophage Immediate Release (GIR) tablet Sino-American Shanghai Squibb (SASS)/China) on Day 1 in treatment period 1 followed by a single oral dose of 500 mg reference GIR (Merck Santé in Semoy (MSS)/France) on Day 8 in treatment period 2 under fasting condition. There was a wash-out period of 7 days between each treatment period.

    Drug: Test GIR · Drug: Reference GIR

  • Experimental
    First Reference GIR (Fasting), Then Test GIR (Fasting)

    Participants received a single oral dose of 500 mg of reference GIR tablet (MSS/France) on Day 1 in treatment period 1 followed by a single oral dose of 500 mg test GIR (SASS/China) on Day 8 in treatment period 2 under fasting condition. There was a wash-out period of 7 days between each treatment period.

    Drug: Test GIR · Drug: Reference GIR

  • Experimental
    First Test GIR (Fed), Then Reference GIR (Fed)

    Participants received a single oral dose of 500 mg of test GIR tablet (SASS/ China) on Day 1 in treatment period 1 followed by a single oral dose of 500 mg reference GIR (MSS/France) on Day 8 in treatment period 2 under fed condition. There was a wash-out period of 7 days between each treatment period.

    Drug: Test GIR · Drug: Reference GIR

  • Experimental
    First Reference GIR (Fed), Then Test GIR (Fed)

    Participants received a single oral dose of 500 mg of reference GIR tablet (MSS/ France) on Day 1 in treatment period 1 followed by a single oral dose of 500 mg test GIR (SASS/China) on Day 8 in treatment period 2 under fed condition. There was a wash-out period of 7 days between each treatment period.

    Drug: Test GIR · Drug: Reference GIR

Interventions

  • Participants received 500 milligrams (mg) test GIR in fasting or fed state on either Day 1 (Treatment Period 1) or Day 8 (Treatment Period 2).

    Also known as: Metformin

  • Participants received 500 mg reference GIR in fasting or fed state on either Day 1 (Treatment Period 1) or Day 8 (Treatment Period 2).

    Also known as: Metformin

06

What researchers measure

Primary outcomes

  1. Area Under the Plasma Concentration-Time Curve From Time Zero to the Last Sampling Time (AUC 0-t) of Metformin (GIR Tablet Active Ingredient)

    Area under the plasma concentration vs time curve from time zero to the last sampling time t at which the concentration was at or above the lower limit of quantification (LLQ). AUC0-t was to be calculated according to the mixed log-linear trapezoidal rule.

    Time frame: Pre-dose, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 14 hours post-dose on Day 1; 24 and 36 hours post-dose on Day 2; 48 hours post-dose on Day 3

  2. Maximum Observed Plasma Concentration (Cmax) of Metformin (GIR Tablet Active Ingredient)

    Pharmacokinetic (PK) parameter Cmax was obtained directly from the concentration versus time curve.

    Time frame: Pre-dose, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 14 hours post-dose on Day 1; 24 and 36 hours post-dose on Day 2; 48 hours post-dose on Day 3

Secondary outcomes

  1. Time to Reach Maximum Plasma Concentration of Metformin (GIR Tablet Active Ingredient)

    Time to reach the maximum plasma concentration (Tmax) was obtained directly from the concentration versus time curve.

    Time frame: Pre-dose, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 14 hours post-dose on Day 1; 24 and 36 hours post-dose on Day 2; 48 hours post-dose on Day 3

  2. Apparent Terminal Half-Life (t1/2) of Metformin (GIR Tablet Active Ingredient)

    Terminal half-life is the time measured for the concentration to decrease by one half. Terminal half-life calculated by natural log 2 divided by λz.

    Time frame: Pre-dose, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 14 hours post-dose on Day 1; 24 and 36 hours post-dose on Day 2; 48 hours post-dose on Day 3

  3. Area Under the Plasma Concentration-Time Curve From Time 0 to Infinity (AUCinf) of Metformin (GIR Tablet Active Ingredient)

    AUC0-inf was calculated by combining AUC0-t and AUCextra. AUC extra represents an extrapolated value obtained by Clast/ λz, where Clast is the calculated plasma concentration at the last sampling time point at which the measured plasma concentration is at or above the Lower Limit of quantification (LLQ) and λz is the apparent terminal rate constant determined by log-linear regression analysis of the measured plasma concentrations of the terminal log-linear phase.

    Time frame: Pre-dose, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 14 hours post-dose on Day 1; 24 and 36 hours post-dose on Day 2; 48 hours post-dose on Day 3

  4. Area Under the Plasma Concentration-Time Curve From Time Tlast Extrapolated to Infinity (AUCextra) of Metformin (GIR Tablet Active Ingredient)

    AUCextra% was defined as area under the curve from time tlast extrapolated to infinity as percentage of AUC 0-infinity. Here, tlast is the last sampling time at which the concentration is at or above the lower limit of quantification.

    Time frame: Pre-dose, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 14 hours post-dose on Day 1; 24 and 36 hours post-dose on Day 2; 48 hours post-dose on Day 3

  5. Elimination Rate Constant (λz) of Metformin (GIR Tablet Active Ingredient)

    λz was determined from the terminal slope of the log-transformed plasma concentration curve using linear regression method.

    Time frame: Pre-dose, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 14 hours post-dose on Day 1; 24 and 36 hours post-dose on Day 2; 48 hours post-dose on Day 3

  6. Total Body Clearance (CL/f) of Metformin (GIR Tablet Active Ingredient)

    Clearance of a drug is a measure of the rate at which a drug is metabolized or eliminated by normal biological processes.

    Time frame: Pre-dose, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 14 hours post-dose on Day 1; 24 and 36 hours post-dose on Day 2; 48 hours post-dose on Day 3

  7. Apparent Volume of Distribution at After Extravascular Administration (Vz/f) of Metformin (GIR Tablet Active Ingredient)

    Vz/f is defined as the distribution of a study drug between plasma and the rest of the body after oral dosing.

    Time frame: Pre-dose, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 14 hours post-dose on Day 1; 24 and 36 hours post-dose on Day 2; 48 hours post-dose on Day 3

  8. Apparent Volume of Distribution at Steady-State After Extravascular Administration (Vss/f) of Metformin

    Vss/F was derived from concentration versus time data for all participants.

    Time frame: Pre-dose, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 14 hours post-dose on Day 1; 24 and 36 hours post-dose on Day 2; 48 hours post-dose on Day 3

  9. Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious TEAEs

    An Adverse event (AE) was defined as any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease associated with the use of study drug, whether or not considered related to the study drug or worsening of pre-existing medical condition, whether or not related to study drug. A serious adverse event (SAE) was an AE that resulted in any of the following outcomes: death; life threatening; persistent/significant disability/incapacity; initial or prolonged inpatient hospitalization; congenital anomaly/birth defect or was otherwise considered medically important. An AE was considered as 'treatment emergent' if it occurred after the first drug administration of each period or if it was present prior to drug administration but exacerbated after the drug administration. TEAEs included both Serious TEAEs and non-serious TEAEs.

    Time frame: Baseline up to Day 15

  10. Number of Participants With Clinically Significant Abnormalities in Vital Signs, Laboratory Parameters, Physical Examination Findings and 12-lead Electrocardiogram (ECG) Findings

    The laboratory measurements included hematology, blood chemistry and urinalysis. Vital sign assessment included blood pressure, pulse rate and body temperature. ECG parameters included heart rate, PR, QRS,QT, RR, QTcB and QTcF Here, we are reporting number of participants with clinically significant abnormalities in Vital signs, laboratory parameters, physical findings and ECG findings.

    Time frame: Baseline up to Day 15

07

Results

Posted Jul 15, 2019

Participant flow

Treatment Period 1 (Day 1-Day 3)
Participant flow — Treatment Period 1 (Day 1-Day 3)
MilestoneFirst Test GIR (Fasting), Then Reference GIR (Fasting)First Reference GIR (Fasting), Then Test GIR (Fasting)First Test GIR (Fed), Then Reference GIR (Fed)First Reference GIR (Fed), Then Test GIR (Fed)
Started131399
Completed131399
Not completed0000
Treatment Period 2 (Day 8- Day 10)
Participant flow — Treatment Period 2 (Day 8- Day 10)
MilestoneFirst Test GIR (Fasting), Then Reference GIR (Fasting)First Reference GIR (Fasting), Then Test GIR (Fasting)First Test GIR (Fed), Then Reference GIR (Fed)First Reference GIR (Fed), Then Test GIR (Fed)
Started131399
Completed131399
Not completed0000

Outcome measures

PrimaryArea Under the Plasma Concentration-Time Curve From Time Zero to the Last Sampling Time (AUC 0-t) of Metformin (GIR Tablet Active Ingredient)

Area under the plasma concentration vs time curve from time zero to the last sampling time t at which the concentration was at or above the lower limit of quantification (LLQ). AUC0-t was to be calculated according to the mixed log-linear trapezoidal rule.

Time frame:
Pre-dose, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 14 hours post-dose on Day 1; 24 and 36 hours post-dose on Day 2; 48 hours post-dose on Day 3
Reported as:
Geometric mean · nanogram hour per milliliter (ng*h/mL)
Area Under the Plasma Concentration-Time Curve From Time Zero to the Last Sampling Time (AUC 0-t) of Metformin (GIR Tablet Active Ingredient)
nanogram hour per milliliter (ng*h/mL)Treatment A: Test GIR (Fasting)Treatment B Reference GIR (Fasting)Treatment A: Test GIR (Fed)Treatment B: Reference GIR (Fed)
Area Under the Plasma Concentration-Time Curve From Time Zero to the Last Sampling Time (AUC 0-t) of Metformin (GIR Tablet Active Ingredient)6260 ± 22.46280 ± 16.34950 ± 25.65020 ± 23.3
Statistical analysis
  • Treatment A: Test GIR (Fasting) vs Treatment B Reference GIR (Fasting) · Ratio of geometric leastsquare(ls) mean%: 99.76 · 90% CI 92.84 to 107.20
  • Treatment A: Test GIR (Fed) vs Treatment B: Reference GIR (Fed) · Ratio of geometric ls mean percentage: 98.67 · 90% CI 91.25 to 106.69
PrimaryMaximum Observed Plasma Concentration (Cmax) of Metformin (GIR Tablet Active Ingredient)

Pharmacokinetic (PK) parameter Cmax was obtained directly from the concentration versus time curve.

Time frame:
Pre-dose, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 14 hours post-dose on Day 1; 24 and 36 hours post-dose on Day 2; 48 hours post-dose on Day 3
Reported as:
Geometric mean · ng/mL
Maximum Observed Plasma Concentration (Cmax) of Metformin (GIR Tablet Active Ingredient)
ng/mLTreatment A: Test GIR (Fasting)Treatment B Reference GIR (Fasting)Treatment A: Test GIR (Fed)Treatment B: Reference GIR (Fed)
Maximum Observed Plasma Concentration (Cmax) of Metformin (GIR Tablet Active Ingredient)1110 ± 30.11110 ± 22.7711 ± 22.4700 ± 18.6
Statistical analysis
  • Treatment A: Test GIR (Fasting) vs Treatment B Reference GIR (Fasting) · Ratio of geometric ls mean percentage: 99.62 · 90% CI 92.69 to 106.77
  • Treatment A: Test GIR (Fed) vs Treatment B: Reference GIR (Fed) · Ratio of geometric ls mean percentage: 101.50 · 90% CI 93.72 to 109.92
SecondaryTime to Reach Maximum Plasma Concentration of Metformin (GIR Tablet Active Ingredient)

Time to reach the maximum plasma concentration (Tmax) was obtained directly from the concentration versus time curve.

Time frame:
Pre-dose, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 14 hours post-dose on Day 1; 24 and 36 hours post-dose on Day 2; 48 hours post-dose on Day 3
Reported as:
Median · hours
Time to Reach Maximum Plasma Concentration of Metformin (GIR Tablet Active Ingredient)
hoursTreatment A: Test GIR (Fasting)Treatment B Reference GIR (Fasting)Treatment A: Test GIR (Fed)Treatment B: Reference GIR (Fed)
Time to Reach Maximum Plasma Concentration of Metformin (GIR Tablet Active Ingredient)2.00 (1.00 to 4.00)2.00 (1.00 to 4.00)2.75 (1.50 to 5.00)2.75 (1.00 to 4.00)
Statistical analysis
  • Treatment A: Test GIR (Fasting) vs Treatment B Reference GIR (Fasting) · Median difference: 0.00 · 90% CI -0.25 to 0.25
  • Treatment A: Test GIR (Fed) vs Treatment B: Reference GIR (Fed) · Median difference: 0.25 · 90% CI -0.25 to 0.50
SecondaryApparent Terminal Half-Life (t1/2) of Metformin (GIR Tablet Active Ingredient)

Terminal half-life is the time measured for the concentration to decrease by one half. Terminal half-life calculated by natural log 2 divided by λz.

Time frame:
Pre-dose, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 14 hours post-dose on Day 1; 24 and 36 hours post-dose on Day 2; 48 hours post-dose on Day 3
Reported as:
Geometric mean · hours
Apparent Terminal Half-Life (t1/2) of Metformin (GIR Tablet Active Ingredient)
hoursTreatment A: Test GIR (Fasting)Treatment B Reference GIR (Fasting)Treatment A: Test GIR (Fed)Treatment B: Reference GIR (Fed)
Apparent Terminal Half-Life (t1/2) of Metformin (GIR Tablet Active Ingredient)4.38 ± 40.54.90 ± 47.44.23 ± 45.64.16 ± 67.3
SecondaryArea Under the Plasma Concentration-Time Curve From Time 0 to Infinity (AUCinf) of Metformin (GIR Tablet Active Ingredient)

AUC0-inf was calculated by combining AUC0-t and AUCextra. AUC extra represents an extrapolated value obtained by Clast/ λz, where Clast is the calculated plasma concentration at the last sampling time point at which the measured plasma concentration is at or above the Lower Limit of quantification (LLQ) and λz is the apparent terminal rate constant determined by log-linear regression analysis of the measured plasma concentrations of the terminal log-linear phase.

Time frame:
Pre-dose, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 14 hours post-dose on Day 1; 24 and 36 hours post-dose on Day 2; 48 hours post-dose on Day 3
Reported as:
Geometric mean · ng*h/mL
Area Under the Plasma Concentration-Time Curve From Time 0 to Infinity (AUCinf) of Metformin (GIR Tablet Active Ingredient)
ng*h/mLTreatment A: Test GIR (Fasting)Treatment B Reference GIR (Fasting)Treatment A: Test GIR (Fed)Treatment B: Reference GIR (Fed)
Area Under the Plasma Concentration-Time Curve From Time 0 to Infinity (AUCinf) of Metformin (GIR Tablet Active Ingredient)6520 ± 20.26410 ± 16.05070 ± 25.05160 ± 21.2
Statistical analysis
  • Treatment A: Test GIR (Fasting) vs Treatment B Reference GIR (Fasting) · Ratio of geometric ls mean percentage: 101.26 · 90% CI 94.33 to 108.69
  • Treatment A: Test GIR (Fed) vs Treatment B: Reference GIR (Fed) · Ratio of geometric ls mean percentage: 98.17 · 90% CI 91.61 to 105.21
SecondaryArea Under the Plasma Concentration-Time Curve From Time Tlast Extrapolated to Infinity (AUCextra) of Metformin (GIR Tablet Active Ingredient)

AUCextra% was defined as area under the curve from time tlast extrapolated to infinity as percentage of AUC 0-infinity. Here, tlast is the last sampling time at which the concentration is at or above the lower limit of quantification.

Time frame:
Pre-dose, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 14 hours post-dose on Day 1; 24 and 36 hours post-dose on Day 2; 48 hours post-dose on Day 3

No measurements were reported for this outcome.

SecondaryElimination Rate Constant (λz) of Metformin (GIR Tablet Active Ingredient)

λz was determined from the terminal slope of the log-transformed plasma concentration curve using linear regression method.

Time frame:
Pre-dose, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 14 hours post-dose on Day 1; 24 and 36 hours post-dose on Day 2; 48 hours post-dose on Day 3

No measurements were reported for this outcome.

SecondaryTotal Body Clearance (CL/f) of Metformin (GIR Tablet Active Ingredient)

Clearance of a drug is a measure of the rate at which a drug is metabolized or eliminated by normal biological processes.

Time frame:
Pre-dose, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 14 hours post-dose on Day 1; 24 and 36 hours post-dose on Day 2; 48 hours post-dose on Day 3
Reported as:
Geometric mean · liter per hour
Total Body Clearance (CL/f) of Metformin (GIR Tablet Active Ingredient)
liter per hourTreatment A: Test GIR (Fasting)Treatment B Reference GIR (Fasting)Treatment A: Test GIR (Fed)Treatment B: Reference GIR (Fed)
Total Body Clearance (CL/f) of Metformin (GIR Tablet Active Ingredient)76.7 ± 20.278.0 ± 16.098.6 ± 25.096.8 ± 21.2
SecondaryApparent Volume of Distribution at After Extravascular Administration (Vz/f) of Metformin (GIR Tablet Active Ingredient)

Vz/f is defined as the distribution of a study drug between plasma and the rest of the body after oral dosing.

Time frame:
Pre-dose, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 14 hours post-dose on Day 1; 24 and 36 hours post-dose on Day 2; 48 hours post-dose on Day 3
Reported as:
Geometric mean · liter
Apparent Volume of Distribution at After Extravascular Administration (Vz/f) of Metformin (GIR Tablet Active Ingredient)
literTreatment A: Test GIR (Fasting)Treatment B Reference GIR (Fasting)Treatment A: Test GIR (Fed)Treatment B: Reference GIR (Fed)
Apparent Volume of Distribution at After Extravascular Administration (Vz/f) of Metformin (GIR Tablet Active Ingredient)485 ± 46.6551 ± 52.5602 ± 34.3581 ± 73.1
SecondaryApparent Volume of Distribution at Steady-State After Extravascular Administration (Vss/f) of Metformin

Vss/F was derived from concentration versus time data for all participants.

Time frame:
Pre-dose, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 14 hours post-dose on Day 1; 24 and 36 hours post-dose on Day 2; 48 hours post-dose on Day 3

No measurements were reported for this outcome.

SecondaryNumber of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious TEAEs

An Adverse event (AE) was defined as any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease associated with the use of study drug, whether or not considered related to the study drug or worsening of pre-existing medical condition, whether or not related to study drug. A serious adverse event (SAE) was an AE that resulted in any of the following outcomes: death; life threatening; persistent/significant disability/incapacity; initial or prolonged inpatient hospitalization; congenital anomaly/birth defect or was otherwise considered medically important. An AE was considered as 'treatment emergent' if it occurred after the first drug administration of each period or if it was present prior to drug administration but exacerbated after the drug administration. TEAEs included both Serious TEAEs and non-serious TEAEs.

Time frame:
Baseline up to Day 15
Reported as:
Count of participants · Participants
Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious TEAEs
ParticipantsTreatment A: Test GIR (Fasting)Treatment B Reference GIR (FastingTreatment A: Test GIR (Fed)Treatment B: Reference GIR (Fed)
Any TEAE2223
Serious TEAE0000
SecondaryNumber of Participants With Clinically Significant Abnormalities in Vital Signs, Laboratory Parameters, Physical Examination Findings and 12-lead Electrocardiogram (ECG) Findings

The laboratory measurements included hematology, blood chemistry and urinalysis. Vital sign assessment included blood pressure, pulse rate and body temperature. ECG parameters included heart rate, PR, QRS,QT, RR, QTcB and QTcF Here, we are reporting number of participants with clinically significant abnormalities in Vital signs, laboratory parameters, physical findings and ECG findings.

Time frame:
Baseline up to Day 15
Reported as:
Count of participants · Participants
Number of Participants With Clinically Significant Abnormalities in Vital Signs, Laboratory Parameters, Physical Examination Findings and 12-lead Electrocardiogram (ECG) Findings
ParticipantsTreatment A: Test GIR (Fasting)Treatment B Reference GIR (Fasting)Treatment A: Test GIR (Fed)Treatment B: Reference GIR (Fed)
Vital Signs0000
Laboratory Parameters0000
Physical Examination0000
12-Lead Electrocardiogram (ECG)0000

Adverse events

Collected over Baseline up to Day 15. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Treatment A Test GIR (Fasting)0/26 (0%)0/26 (0%)2/26 (7.7%)
Treatment B Reference GIR (Fasting)0/26 (0%)0/26 (0%)2/26 (7.7%)
Treatment A: Test GIR (Fed)0/18 (0%)0/18 (0%)2/18 (11.1%)
Treatment B: Reference GIR (Fed)0/18 (0%)0/18 (0%)3/18 (16.7%)
Most frequent other events
Most frequent other events
EventTreatment A Test GIR (Fasting)Treatment B Reference GIR (Fasting)Treatment A: Test GIR (Fed)Treatment B: Reference GIR (Fed)
DiarrheaGastrointestinal disorders1/262/261/182/18
Abdominal distensionGastrointestinal disorders0/260/262/181/18
Abdominal painGastrointestinal disorders0/260/261/181/18
Frequent bowel movementsGastrointestinal disorders0/260/260/181/18
AnemiaBlood and lymphatic system disorders1/260/260/180/18

Baseline characteristics

Age, Continuous
Age, Continuous(years)First Test GIR (Fasting), Then Reference GIR (Fasting)First Reference GIR (Fasting), Then Test GIR (Fasting)First Test GIR (Fed), Then Reference GIR (Fed)First Reference GIR (Fed), Then Test GIR (Fed)Total
Mean32.8 ± 7.9731.5 ± 7.3929.8 ± 9.0132.2 ± 7.0331.7 ± 7.65
Sex: Female, Male
Sex: Female, Male(Participants)First Test GIR (Fasting), Then Reference GIR (Fasting)First Reference GIR (Fasting), Then Test GIR (Fasting)First Test GIR (Fed), Then Reference GIR (Fed)First Reference GIR (Fed), Then Test GIR (Fed)Total
Female343414
Male1096530
Race (NIH/OMB)
Race (NIH/OMB)(Participants)First Test GIR (Fasting), Then Reference GIR (Fasting)First Reference GIR (Fasting), Then Test GIR (Fasting)First Test GIR (Fed), Then Reference GIR (Fed)First Reference GIR (Fed), Then Test GIR (Fed)Total
American Indian or Alaska Native00000
Asian13139944
Native Hawaiian or Other Pacific Islander00000
Black or African American00000
White00000
More than one race00000
Unknown or Not Reported00000
08

Study locations

1 site
  • Xuanwu Hospital
    Beijing, 100053, China
09

References and documents

Publications

  • Hu C, Gao D, Li D, Zhou D, Zhang L. Chinese- and French-Manufactured Immediate-Release Glucophage(R) Bioequivalence: A Randomized, Open-Label, Crossover Study. Drugs R D. 2022 Dec;22(4):301-309. doi: 10.1007/s40268-022-00405-3. Epub 2022 Oct 20. PubMed 36264446 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2018 to primary completion in Jan 2018, 0 months.

Results were first posted in Jul 2019, 1 year 5 months after primary completion.

Of 171 industry-sponsored phase 1 interventional studies under Diabetes Mellitus, half reached primary completion within 6 months of starting (the median), counting those still running; a quarter within 2 and three quarters within 10. This study's 0 months is below that.

Counting every sponsor, half of 247 studies reached it within 7 months; a quarter within 3 and three quarters within 17.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 22, 2017
First posted
Jan 8, 2018
StartActual
Jan 10, 2018
Primary completionActual
Jan 29, 2018
CompletionActual
Jan 29, 2018
Results first posted
Jul 15, 2019
Last update
Jul 15, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 15, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03393208
Responsible party
Sponsor
First posted
Jan 8, 2018
Start date
Jan 10, 2018
Primary completion
Jan 29, 2018
Completion
Jan 29, 2018
Results posted
Jul 15, 2019
Last update
Jul 15, 2019

Study contacts

Medical Responsible
study director · Merck KGaA, Darmstadt, Germany

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Metformin

Start the discussion